Last reviewed · How we verify
Methergine
Methergine is a Small molecule drug developed by University of South Florida. It is currently FDA-approved for Postabortal Hemorrhage, Postpartum hemorrhage. Also known as: methylergonovine maleate.
At a glance
| Generic name | Methergine |
|---|---|
| Also known as | methylergonovine maleate |
| Sponsor | University of South Florida |
| Target | 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 1A |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Postabortal Hemorrhage
- Postpartum hemorrhage
Common side effects
- Hypertension
- Abdominal pain
- Nausea
- Vomiting
- Seizure
- Headache
- Hypotension
Serious adverse events
- Acute myocardial infarction
- Coronary arterial spasm
- Vasospasm
- Vasoconstriction
- Ventricular fibrillation
- Ventricular tachycardia
- Cerebrovascular accident
- Anaphylaxis
- Water intoxication
- Thrombophlebitis
Key clinical trials
- Ergometrine Versus Carbetocin to Decrease Blood Loss in Myomectomy (NA)
- Cooling the Uterus in C-section After Dysfunctional Labor (NA)
- Prophylactic Regimen of Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative for Primary Prevention of Postpartum Hemorrhage in Intrapartum Cesarean Section Versus Intravenous Carbetocin Alone (NA)
- Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial (PHASE4)
- Prophylactic Methylergonovine for Twin Cesarean (PHASE4)
- Oxytocin Bolus Versus Infusion in Elective Cesarean Section" (PHASE4)
- Misoprostol Versus Active Management of Labour in CS (PHASE1)
- Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methergine CI brief — competitive landscape report
- Methergine updates RSS · CI watch RSS
- University of South Florida portfolio CI
Frequently asked questions about Methergine
What is Methergine?
Methergine is a Small molecule drug developed by University of South Florida, indicated for Postabortal Hemorrhage, Postpartum hemorrhage.
What is Methergine used for?
Methergine is indicated for Postabortal Hemorrhage, Postpartum hemorrhage.
Who makes Methergine?
Methergine is developed and marketed by University of South Florida (see full University of South Florida pipeline at /company/university-of-south-florida).
Is Methergine also known as anything else?
Methergine is also known as methylergonovine maleate.
What development phase is Methergine in?
Methergine is FDA-approved (marketed).
What are the side effects of Methergine?
Common side effects of Methergine include Hypertension, Abdominal pain, Nausea, Vomiting, Seizure, Headache. Serious adverse events: Acute myocardial infarction, Coronary arterial spasm, Vasospasm, Vasoconstriction.
What does Methergine target?
Methergine targets 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 1A.
Related
- Target: All drugs targeting 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 1A
- Manufacturer: University of South Florida — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Postabortal Hemorrhage
- Indication: Drugs for Postpartum hemorrhage
- Also known as: methylergonovine maleate
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing